Dare Bioscience Q1 EPS $(0.07) Misses $(0.06) Estimate
Portfolio Pulse from Benzinga Newsdesk
Dare Bioscience (NASDAQ:DARE) reported Q1 EPS losses of $(0.07), missing the consensus estimate of $(0.06) by 16.67%. This represents a 22.22% improvement over the $(0.09) per share loss from the same period last year.
May 14, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Dare Bioscience reported a Q1 EPS loss of $(0.07), missing estimates by 16.67% but improved from last year's $(0.09) loss.
Missing the EPS estimate typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. However, the improvement over last year's loss may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100